Share your experiences of biosimilar medications
Along with NRAS, Crohn’s and Colitis UK and the Psoriasis Association, NASS want to understand your experiences of switching to a biosimilar medication.
Physical branch meetings are currently cancelled due to COVID-19. However there are virtual activities being run by some branches. Please contact your local branch for more information.
We hope you find the information on these pages helpful. Our team is working tirelessly to provide up to date advice in relation to the COVID-19/Coronavirus pandemic. Record numbers of people are now turning to NASS for support, and we hope to be here for everyone. Our helpline and advice service are only possible thanks to donations from people like you.
If you are able to make a donation to NASS today, we'd be so grateful.
DONATE
Search results for: 'biosimilar'
Along with NRAS, Crohn’s and Colitis UK and the Psoriasis Association, NASS want to understand your experiences of switching to a biosimilar medication.
Discover the role of biosimilars in the treatment of axial SpA (AS)
The patent for adalimumab, brand name Humira® has expired. New biosimilar versions of the drug are now available.
NASS knows that not everyone in the UK gets the same standard of care for their axial SpA (AS) – that’s why we've launched our new campaign Every Patient, Every Time.
NASS works closely with the National Institute for Health and Care Excellence and Scottish Medicines Consortium, contributing to the development of the Guideline and Quality Standard for Spondyloarthritis, and offering patient perspective on drug appraisals
Spring 2016 edition of AS News magazine
Discover the role of NSAIDs in managing axial SpA (AS)
Discover the role of DMARDs in managing axial SpA (AS)
Discover the role of biologic therapy in managing axial SpA (AS)